3/24/2023  5:29:56 PM Chg. +0.29 Volume Bid5:30:00 PM Ask5:30:00 PM Market Capitalization Dividend Y. P/E Ratio
100.25EUR +0.29% 39,439
Turnover: 2.21 mill.
-Bid Size: - -Ask Size: - 15.88 bill.EUR 0.62% 29.42

Business description

bioMérieux S.A. is one of the world leaders in the field of in vitro diagnostics for over 50 years. bioMérieux is present in more than 160 countries through 42 subsidiaries and a large network of distributors. bioMérieux provides diagnostic solutions (reagents, instruments, software and services) which determine the source of disease and contamination to improve patient health and ensure product safety. In clinical applications, the Company offers a wide range of solutions for managing infectious diseases, cardiovascular diseases and targeted cancers. For the agri-food, cosmetics and pharmaceutical industries, bioMérieux provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing.

Management board & Supervisory board

Jean-Luc Belingard
Management board
Henri Thomasson, Alain Pluquet, Alexandre Mérieux, François Lacoste, Jean-Marc Durano, Marc Mackowiak, Michel Baguenault, Stefan Willemsen, Steve Harbin, Thierry Bernard
Supervisory board
Alexandre Mérieux, Agnès Lemarchand, Alain Mérieux, arie-Hélène Habert-Dassault, Fanny Letier, Frédéric Besème, Harold Boël, Jean-Luc Bélingard, Marie-Paul Kieny, Philippe Archinard

Company data

Name: bioMerieux S.A.
Address: Chemin de l'Orme,F-69280 Marcy l'Etoile
Phone: +33-4-7887-2000
Fax: +33-4-7887-2090
E-mail: -
Internet: www.biomerieux.com
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 33.97%
IPO date: -

Investor relations

Name: Sylvain Morgeau
IR phone: +33-4-7887-2237
IR Fax: -
IR e-mail: investor.relations@b...eux.com investor.relations@biomerieux.com

Company calendar

CW 17 | 4/27/2023 Interim Report 1st Quarter/3 Months
CW 21 | 5/23/2023 General Shareholder Meeting
CW 35 | 9/1/2023 Interim Report 2nd Quarter/6 Months
CW 43 | 10/26/2023 Interim Report 3rd Quarter/9 Months

Main Shareholders

Institut Mérieux
Sofina SA
eigene Aktien